Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy
about
Primary central nervous system lymphoma: essential points in diagnosis and management.Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma.Advances in the treatment of newly diagnosed primary central nervous system lymphomas.Primary central nervous system lymphoma
P2860
Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment of newly diagnosed B ...... intrathecal immunochemotherapy
@en
Treatment of newly diagnosed B ...... ntrathecal immunochemotherapy.
@nl
type
label
Treatment of newly diagnosed B ...... intrathecal immunochemotherapy
@en
Treatment of newly diagnosed B ...... ntrathecal immunochemotherapy.
@nl
prefLabel
Treatment of newly diagnosed B ...... intrathecal immunochemotherapy
@en
Treatment of newly diagnosed B ...... ntrathecal immunochemotherapy.
@nl
P2093
P2860
P356
P1433
P1476
Treatment of newly diagnosed B ...... intrathecal immunochemotherapy
@en
P2093
Chunhui Zhou
Jianliang Shen
Wenjie Yin
P2860
P304
25783-25790
P356
10.18632/ONCOTARGET.8370
P407
P50
P577
2016-05-01T00:00:00Z